comparemela.com

Page 12 - Fabio Chianelli News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DiagnaMed Announces Listing on OTCQB in the United States

TORONTO, April 11, 2023 DiagnaMed Holdings Corp. , a digital health AI company, is pleased to announce that effective April 11, 2023, the Company is listed on the OTCQB Venture Market under. | April 11, 2023

United statesFabio chianelliRegulation services providerExchange commissionBrain health ai platformGroup incNeither the canadian securities exchangeDiagnamed holdings corpCanadian securities exchangeMed holdingsDepository trust companyUnited states securitiesBrain healthDiagnamed holdings corp stock exchangePress releaseArket dmed ca25245d1033

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson s Disease

TORONTO, March 29, 2023 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration for advancing. | March 29, 2023

Fabio chianelliDrug administrationCompany or pharmatherPharmather holdings ltdRegulation services providerNeither the canadian securities exchangeMother holdingsFast trackTreating motor disordersLevodopa induced dyskinesiasCanadian securities exchangePharmather holdings ltd stock exchangePress releaseOr phrm ca71716h1082

DiagnaMed Announces Appointment of New Director

13.02.2023 - TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) - DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, announced today that Ms. Emily Davis resigned as director of the Board of Directors (the .

Fabio chianelliNeither the canadian securities exchangeBrain health ai platformDiagnamed holdings corpRegulation services providerDiagnamed holdingsBrain healthCanadian securities exchange

Oral Ketamine Gets Orphan Drug Status for Rett Syndrome

The FDA has granted Orphan Drug designation to Ketarx (racemic ketamine) for the treatment of Rett syndrome.

Fabio chianelliDrug administrationOrphan drug

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2)

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in advancing.

Fabio chianelliPharmather holdings ltdNeither the canadian securities exchangeCompany or pharmatherDrug administrationRegulation services providerMother holdingsOn body pump systemNew drug applicationOn body pumpCanadian securities exchangeCanadian stock exchange phrm cnPharmather holdings ltd

vimarsana © 2020. All Rights Reserved.